A Phase 3, Multicenter, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% and 1.0% Compared to Vehicle in Participants With Dry Eye Disease (VELOS-4)

The objectives of this study are to compare the efficacy and safety of tanfanercept ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.

Start Date01 May 2024

Sponsor / Collaborator

HANALL BIOPHARMA Co., Ltd.

NCT05109702 / CompletedPhase 3

A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye

The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.

Start Date18 Nov 2021

Sponsor / Collaborator

HANALL BIOPHARMA Co., Ltd.

[+1]

CTR20202142 / Active, not recruitingPhase 3

一项评价HBM9036（HL036）滴眼液（0.25%）与安慰剂相比治疗中国中、重度干眼患者的有效性和安全性的3期、多中心、随机、双盲、安慰剂对照研究

[Translation] A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of HBM9036 (HL036) eye drops (0.25%) compared with placebo in the treatment of moderate to severe dry eye in Chinese patients

评价HBM9036（HL036）滴眼液（0.25%）与安慰剂相比治疗中国中、重度干眼患者的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of HBM9036 (HL036) eye drops (0.25%) compared with placebo in the treatment of moderate to severe dry eye in Chinese patients.

Start Date25 Feb 2021

Sponsor / Collaborator

BINEX Co., Ltd.

[+3]

100 Clinical Results associated with Tanfanercept

100 Translational Medicine associated with Tanfanercept

100 Patents (Medical) associated with Tanfanercept

2,123

Literatures (Medical) associated with Tanfanercept

01 Feb 2024·Expert opinion on investigational drugs

Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis

Article

Author: Akhavanrezayat, Amir ; Thng, Zheng Xian ; Or, Christopher Chi Mong ; Shin, Yong Un ; Tran, Anh N T ; Regenold, Jonathan ; Bromeo, Albert John ; Karaca, Irmak ; Ghoraba, Hashem H ; Mohammadi, S Saeed ; Khatri, Anadi ; Than, Ngoc T T ; Nguyen, Quan Dong

INTRODUCTION:

Uveitis is a heterogeneous group of ocular conditions characterized by inflammation of the uveal tract and is one of the leading causes of vision impairment. In developed countries, noninfectious uveitis (NIU) represents most cases and is challenging to treat due to its severity, chronicity, and high recurrence rates. The advent of anti-tumor necrosis factor-α (anti-TNF-α) agents have dramatically improved outcomes and changed treatment paradigms in NIU.

AREAS COVERED:

The index article summarizes the present experience of anti-TNF-α agents in NIU pharmacotherapy and highlights the barriers to further research and development of anti-TNF-α agents for uveitis. Common challenges faced in NIU clinical drugs trials, specific difficulties in anti-TNF-α drug development, and promising competitor drug candidates are discussed and evaluated.

EXPERT OPINION:

Anti-TNF-α agents have revolutionized NIU pharmacotherapy and greatly improved outcomes with good safety profiles. The great success of systemic infliximab and adalimumab in NIU treatment has resulted in little impetus for further development of this class of medication. Attempts have been made to deliver anti-TNF-α agents intravitreally but that has not been successful thus far. With expiring patents, competition from biosimilars and newer, novel molecules, it may not be viable to continue pursuing anti-TNF-α drug development.

01 Jan 2024·Eye (London, England)

The role of the cytokine TNF-α in choroidal neovascularization: a systematic review

Review

Author: Papadopoulos, Zois

TNF-α is a multifunctional cytokine produced by macrophages and T cells. This proinflammatory substance is considered to play a crucial role in the inflammatory process associated with age-related macular degeneration (AMD). The current review aimed to describe evidence for an association between TNF-α and AMD reported in various studies. The MEDLINE, Embase, PubMed and Global Health databases were systematically searched to identify studies that investigated the role of TNF-α in AMD. A total of 24 studies were deemed eligible for the review. To better understand and integrate the evidence, the studies were categorised into four major groups in relation to the role of TNF-α in AMD: (1) those examining biological signalling pathways through which TNF-α exerts its effect; (2) investigating levels of TNF-α; (3) exploring the genetics underlying the role of TNF-α; and (4) assessing anti-TNF-α agents as potential treatments for AMD. TNF-α is thought to directly contribute to choroidal neovascularization (CNV) enhancement and has been shown to exert its effect by augmenting the inflammatory response through other signalling pathways. Additionally, different genes have been found to be associated with activities linked to TNF-α in AMD. Overall, measurement of systemic and local levels of TNF-α has not yielded consistent findings, with variable conclusions for the role of anti-TNF-α agents in remission of AMD symptoms. The role of TNF-α in neovascular AMD is not clear, and not all anti-TNF-α agents are safe. The potential of this cytokine in atrophic AMD has not been examined. Future studies should address these unresolved questions.

01 Jan 2024·BJUI compass

Prostatic urethral lift for subjects in urinary retention (PULSAR): 12‐Month results of a prospective controlled trial compared with real‐world outcomes

Article

Author: Page, Toby ; Eure, Gregg ; Barber, Neil ; Doherty, Ruth ; Kayes, Oliver ; Chin, Peter ; Thiruchelvam, Nikesh ; Gange, Steven ; Mueller, Thomas ; Rochester, Mark ; Kavia, Rajesh

Abstract:

Objective:

To examine the safety and efficacy of prostatic urethral lift (PUL) in acute urinary retention (AUR) patients within a controlled (PULSAR) and real‐world setting (Real‐World Retrospective study).

Materials and methods:

PULSAR was a 12‐month prospective study of PUL in AUR patients (n = 51) performed at six centres in the United Kingdom; enrolled BPH patients aged ≥50 years, with prostate volume of ≤100 cc. AUR was defined as being catheter dependent with at least one prior failed trial without catheter (TWOC) while on an alpha‐blocker. RWR consisted of 3226 consecutive PUL patients across 22 international sites treated between July 2017 and March 2020; 469 of whom were in urinary retention (RWRr), that is, catheter‐dependent at the time of their procedure. Symptom response, uroflow and catheter independence rates were compared between PULSAR and RWRr subjects. A logistical regression model was constructed to evaluate patient baseline and dynamic factors predicting success after the procedure.

Results:

Seventy‐three percent of PULSAR subjects were catheter independent and free from surgical reintervention at 12 months post‐PUL. Success was associated with higher voiding efficiency during the perioperative period. Slightly higher catheter‐independent rates (80%) were seen in RWRr patients; variables that influenced success included age <70 years, lower baseline prostate‐specific antigen (PSA), lower baseline post‐void residual (PVR) and shorter pre‐procedural catheter duration. Logistic regression of the combined PULSAR and RWRr retention groups revealed that procedural age <70 years and higher bladder voiding efficiency (BVE) were associated with success.

Conclusions:

Lower baseline PSA and PVR, younger age and shorter pre‐procedure catheter durations drove successful outcomes in AUR patients undergoing PUL. Post‐PUL voiding efficiencies may help ascertain long‐term response to treatment.

115

News (Medical) associated with Tanfanercept

20 Jun 2024

·www.biospace.com

Prostate Drugs May Find New Use in Reducing Risk of Dementia: Study

Pictured: Concept art showing an elderly woman overlaid with an illustration of a brain/iStock, boonstudio Drugs commonly used for the treatment of enlarged prostate may also help lower the risk of dementia with Lewy bodies, according to a new observational study from the University of Iowa Health Care. Drawing from Merative MarketScan, one of the largest proprietary U.S. healthcare claims databases, University of Iowa researchers identified more than 643,000 men who were starting treatment for benign prostatic hyperplasia with one of six common therapies. Three of these drugs fell under the class of α-1 adrenergic receptor antagonists, better known as α-blockers, which work by inhibiting the contraction of smooth muscles. The researchers focused on terazosin, which is sold by Abbott under the brand name Hytrin, doxazosin, which is marketed by Pfizer as Cardura, and alfuzosin, which is branded as Uroxatral by Sanofi. Alpha-blocker drugs are known to have a unique side effect: they activate a key enzyme involved in the production of ATP, which is the molecular form of cellular energy. In the brain, these drugs can help boost the production of energy and fight neurodegeneration, the University of Iowa scientists hypothesized. As active comparators, the researchers also followed men in Merative MarketScan who were being treated with tamsulosin or with the 5α-reductase inhibitors (5ARI) finasteride and dutasteride, all of which are not known to affect energy production in the brain. The men included in the study had no history of dementia with Lewy bodies (DLB). Participants were then followed until they exited the database or until they developed DLB. After an average follow-up of around three years, the study found that men who were initiated on the three alpha-blocker drugs were 40% less likely to develop DLB than comparators who were on tamsulosin. Compared with men whose enlarged prostates were being treated with 5ARI agents, the risk of DLBA was 27% lower in those taking alpha-blocker drugs. Both effects were statistically significant. By contrast, DLB had a statistically similar likelihood of developing in men being managed with tamsulosin and 5ARIs. These results were robust to several sensitivity analyses, according to researchers. The University of Iowa scientists published their findings Wednesday in Neurology, the medical journal of the American Academy of Neurology. “If terazosin and these similar medications can help slow this progression—if not outright preventing the disease—this would be important to preserving cognitive function and quality of life in people with DLB,” Jacob Simmering, assistant professor of internal medicine at the University of Iowa and lead study author, said in a statement. However, the researchers caution that the study is simply observational in design and only shows that there is a statistical correlation between the use of alpha-blocker drugs and the reduced risk of DLB. It does not establish causation nor does it show any directionality of association, they said. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical Result

28 May 2024

·www.prnewswire.com

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies. Deal value can exceed $300 million USD for the initial product. ROCKVILLE, Md. and SEOUL, South Korea, May 28, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming. This agreement expands the relationship between the companies, which began in 2022 when HanAll made an initial investment in Turn Bio. The terms grant HanAll the right to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic disease. HanAll anticipates leveraging synergies between ophthalmic and otic fields where it has therapeutic expertise and experience, and drawing on Turn Bio's knowledge of cellular reprogramming, mRNAs, and lipid nanoparticles. Aging mitigation and cell reprogramming technologies have been gaining attention for their potential to address the high unmet needs in age-related disorders, particularly in the eye and ear. HanAll has been actively exploring cell reprogramming through open collaborations and a global network. The ERATM technology developed by Turn Bio reverses certain aspects of cellular aging by utilizing a cocktail of mRNA transcription factors specifically designed for transient epigenetic reprogramming. Past attempts at similar technologies have struggled due to the risk of cells differentiating into unforeseen cell types. Turn Bio's technology aims to overcome these challenges by restoring youthful cell function through precise dosing and timing of ERATM while maintaining the original cellular identity, offering promising potential for addressing age-related disorders. Currently, Turn Bio is undertaking pre-clinical research for dermatology and immunology applications. "We're excited to advance into a new phase of development with Turn Bio to explore the potential of its innovative platform in addressing important age-related conditions. This partnership will enhance HanAll's R&D capabilities in mRNA and LNP product development while also providing an opportunity to explore the potential for pipeline expansion," said Sean Jeong, M.D., MBA, CEO of HanAll Biopharma. "This agreement is a testament to the vast opportunities ahead globally as the world's population grows older," said Turn Bio CEO Anja Krammer. "HanAll's commitment is recognition that our innovative ERA™ technology has the potential to revolutionize treatments for myriad conditions associated with aging." The deal, valued over $300 million USD for the first product, is structured around negotiated milestones. About HanAll Biopharma HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with the mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the therapeutic areas of endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Another lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and is also being evaluated in China for the treatment of dry eye disease. HL161ANS, an anti-FcRn antibody targeting multiple indications, and HL192 (ATH-399A), a Nurr1 activator currently targeting Parkinson's Disease, are also being evaluated in Phase 1 clinical studies (healthy volunteers). For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR ([email protected], [email protected]). About Turn Biotechnologies Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERA™ reprogramming technology aims to restore optimal gene expression by combatting the effects of aging in the epigenome. This potentially restores cells' ability to prevent or treat disease and heal or regenerate tissue and helps to fight incurable chronic diseases. Turn Bio's eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types. The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see . or contact Jim Martinez, rightstorygroup / [email protected] or +1 (312) 543-9026. Disclaimer statement The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements HanAll (the company, we) makes concerning its 2024 business and financial outlook and related plans, the therapeutic potential of its product candidates, the intended results of its strategy and the company, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts, the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. These may include various significant factors such as our expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements. In addition, performance may be affected by our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property of technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of product candidates. A further list and description of these risks, uncertainties and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations. SOURCE HanAll Biopharma

Phase 1License out/inPhase 3Phase 2

28 May 2024

·www.prnewswire.com

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

Synergistic collaboration to revolutionize age-related therapies worldwide Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions. The agreement, potentially exceeding $300 million in value for the first of multiple planned products, significantly expands the relationship between the companies. HanAll originally invested in Turn Bio in 2022. A New Frontier in Age-Related Therapies Products resulting from this collaboration will utilize Turn Bio's Epigenetic Reprogramming of Age (ERATM) technology and its novel eTurna™ delivery platform. These cutting-edge technologies aim to restore optimal gene expression, combatting the effects of aging at the cellular level to treat and potentially cure chronic conditions. "This partnership is a milestone for Turn Bio," said company CEO Anja Krammer. "With HanAll's support, we are accelerating the development of transformative therapies for eye and ear indications, which can benefit patients around the world. The potential impact on patients' lives is enormous, and this is just the beginning." HanAll has closely monitored Turn Bio's progress since its initial investment, recognizing the revolutionary potential of its epigenetic reprogramming technology. "Turn Bio's innovative approach to epigenetic reprogramming aligns closely with HanAll's mission to explore innovative medicines to expand our therapeutic area," said Sean Jeong, M.D., MBA, CEO of HanAll Biopharma. "Together, we are poised to pioneer new treatments that address critical unmet needs, particularly in aging-related diseases." Expanding Horizons in Regenerative Medicine The partnership expands Turn Bio's development, which had primarily focused on dermatology and immunology, to two other organs most commonly affected by age-related conditions. This means Turn Bio is working on therapies to treat and potentially cure most diseases caused by aging. "The power of ERA™ technology is that it can rejuvenate cells in virtually any organ in the body," said Turn Bio Co-founder Vittorio Sebastiano, the company's head of research. "This agreement enables us to accelerate our development on multiple fronts to reverse the damage caused by aging and improve the quality of life for older patients." ABOUT TURN BIOTECHNOLOGIES Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERA™ reprogramming technology aims to restore optimal gene expression by combatting the effects of aging in the epigenome. This potentially restores cells' ability to prevent or treat disease and heal or regenerate tissue and helps to fight incurable chronic diseases. Its eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types. The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see . About HanAll Biopharma HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with the mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the therapeutic areas of endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Another lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and is also being evaluated in China for the treatment of dry eye disease. HL161ANS, an anti-FcRn antibody targeting multiple indications, and HL192 (ATH-399A), a Nurr1 activator currently targeting Parkinson's Disease, are also being evaluated in Phase 1 clinical studies (healthy volunteers). For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR ([email protected], [email protected]). FOR MORE INFORMATION, CONTACT: Jim Martinez, rightstorygroup [email protected] or (312) 543-9026 Logo -

License out/inPhase 3Phase 1Phase 2

100 Deals associated with Tanfanercept

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Phase 3	US	HANALL BIOPHARMA Co., Ltd.	10 Mar 2019
Xerophthalmia	Phase 3	-	HANALL BIOPHARMA Co., Ltd.	-
Xerophthalmia	Phase 3	-	Daewoong Pharmaceutical Co., Ltd.	-
Wet Macular Degeneration	Preclinical	KR	HANALL BIOPHARMA Co., Ltd.	27 Jul 2018
Uveitis	Preclinical	KR	HANALL BIOPHARMA Co., Ltd.	17 Jul 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05109702 (CTgov)	Phase 3	Dry Eye Syndromes	260	0.25% Tanfanercept Ophthalmic Solution (0.25% Tanfanercept Ophthalmic Solution)	atsmaktdvv(kcyuvrreyn) = cgrunwjdex dnjhjmvqcn (ijzkqpsazb, lejfxbllpe - rxzntgfmdb) View more	-	23 Oct 2023
				Placebo (Placebo)	atsmaktdvv(kcyuvrreyn) = tohawfkjub dnjhjmvqcn (ijzkqpsazb, nrumcfagsq - fsbgsdhmow) View more
NCT03846453 (VELOS-2, CTgov)	Phase 3	Dry Eye Syndromes	637	HL036 Ophthalmic Solution (0.25% HL036 Ophthalmic Solution)	pknhklnoix(rqxjparxun) = aaowykdccm wsddvkkorp (lmbajtfees, erexpybkpd - saapcjqpym) View more	-	14 Apr 2022
				Placebo (Placebo)	pknhklnoix(rqxjparxun) = qotcihzrra wsddvkkorp (lmbajtfees, ouerodbzjq - pbgaxtwrgk) View more
NCT04092907 (Pubmed)	Phase 2	Dry Eye Syndromes	100	Tanfanercept 0.25%	amqzeotzhj(ezmgtacrpt) = ifnfimazrg rmivfenukb (zlgwcjjtjv, 0.62)	Positive	22 Feb 2022
				Placebo	amqzeotzhj(ezmgtacrpt) = mkbebuxeqz rmivfenukb (zlgwcjjtjv, 0.62)
NCT03334539 (CTgov)	Phase 2	Dry Eye Syndromes	150	HL036 ophthalmic solution (0.10% HL036 Ophthalmic Solution)	ryozrozgkq(kacpdwqoby) = chhilmylts nshgcmhwtw (dothlmqhgm, mkpjdphtxn - vnawtaclsb) View more	-	26 Jan 2022
				HL036 ophthalmic solution (0.25% HL036 Ophthalmic Solution)	ryozrozgkq(kacpdwqoby) = uagenycqtg nshgcmhwtw (dothlmqhgm, bjubxiotza - whkswdttvw) View more
NCT04092907 (CTgov)	Phase 2	Dry Eye Syndromes	100	HBM9036 0.25% Ophthalmic Solution (HBM9036 0.25% Ophthalmic Solution)	tuidmasbtt(bvvxhnlklv) = mvlhnlcvkd ohhihzhool (hesnisngtm, nllwpmxvrz - gccslvqxww) View more	-	11 Aug 2021
				placebo (Placebo Ophthalmic Solution)	tuidmasbtt(bvvxhnlklv) = tdbzsyalyj ohhihzhool (hesnisngtm, fxpgfnsmsl - oeevornyal) View more
NCT03846453 (VELOS-2, Corporate Publications) Manual	Phase 3	Dry Eye Syndromes	637	HL036	fmcvsqjbje(dizcbftbvk): P-Value = 0.0624 View more	Positive	28 Jan 2020
				Placebo
EULAR2018	Not Applicable	-	415	anti-tnf-alpha	xjfinhihpk(ragnsrfhuw) = rliacmledd ifgnrllszb (awjaidzlfs, 24.87 - 77.13)	-	13 Jun 2018
				anti-tnf-alpha	xjfinhihpk(ragnsrfhuw) = lscgxxhtun ifgnrllszb (awjaidzlfs, 28.39 - 71.61)
ACR2014	Not Applicable	Rheumatoid Arthritis	-	MTX monotherapy	lwzrjtletu(fexxdpcryy) = ikzhvezfwa fxvnqkeepl (lrgooyogxu )	Positive	14 Nov 2014
				TNFi treatment in combination with MTX or leflunomide	lmfwyfbjft(njzlzbitml) = gqfvdtuvzk jypuqunfek (qdwnuyusmt ) View more
EULAR2008	Not Applicable	Ankylosing Spondylitis metalloproteinase 3 (MMP-3) \| bone alkaline phospahtase (BAP) \| vasoendothelial growth factor (VEGF) ... View more	-	Adalimumab-treated AS patients	dxbpowessc(bmcsdiggnd) = The mean BASDAI decreased by 2.8 points after 36-52 weeks innowaojar (sqvelykjdi ) View more	-	11 Jun 2008
EULAR2003	Not Applicable	anti-TNF-alpha	300	Anti-TNF-alpha therapies	jrbixigyqa(nrboutgafq) = xzllpzftta iewqzyeivp (ruwbxnvsbm ) View more	-	18 Jun 2003
				MTX	jrbixigyqa(nrboutgafq) = nczbhnrnkl iewqzyeivp (ruwbxnvsbm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis